Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 5/8/2020
SIETES contiene 93082 citas

 1 a 20 de 63 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Maladies auto-immunes d'origine médicamenteuse. Prescrire 2017;37:346-53. [Ref.ID 101654]
2.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
5. Cita con resumen
Chang C, Gershwin ME. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011;34:357-74. [Ref.ID 90404]
Anónimo. Pazopanib. Cancer du rein: quel bénéfice pour tant de risques?. Prescrire 2010;30:812-5. [Ref.ID 89595]
7. Cita con resumen
The INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009;361:1548-59. [Ref.ID 87014]
8.Tiene citas relacionadas
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56. [Ref.ID 83756]
9.Tiene citas relacionadas Cita con resumen
Knox JJ. Progression-free survival as endpoint in metastatic RCC?. Lancet 2008;372:427-9. [Ref.ID 83753]
Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf 2007;29:567-86. [Ref.ID 79416]
12.Tiene citas relacionadas Cita con resumen
Angus B, on behalf of the ESPRIT STALWART and SILCAAT trial steering committees. Interleukin 2 treatment in HIV-1 infection. Lancet 2006;367:1054-5. [Ref.ID 76490]
13.Tiene citas relacionadas Cita con resumen
Roca B. Interleukin 2 treatment in HIV-1 infection. Lancet 2006;367:1054-5. [Ref.ID 76489]
Sloand EM, Scheinberg P, Maciejewski J, Young NS. Brief communication: successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (declizumab). Ann Intern Med 2006;144:181-5. [Ref.ID 76247]
15.Tiene citas relacionadas Cita con resumen
Vento S, Cainelli F, Temesgen Z. Interleukin-2 therapy and CD4 + T cells in HIV-1 infection. Lancet 2006;367:93-5. [Ref.ID 75922]
16.Tiene citas relacionadas Cita con resumen
Routy J-P. Valproic acid: a potential role in treating latent HIV infection. Lancet 2005;366:523-4. [Ref.ID 74625]
Brun Romero FM, Terrón Pernía JA. Reacción ampollar tras la administración de interleucina 2. Med Clin (Barc) 2004;123:637. [Ref.ID 71976]
18. Cita con resumen
Bradbury J. Beyond pills and jabs. Lancet 2003;362:1984-5. [Ref.ID 68468]
20. Cita con resumen
Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003;326:789-91. [Ref.ID 65717]
Seleccionar todas
 1 a 20 de 63 siguiente >>